Holen Sie sich die Stockscreener-App
0.7755
4.73%
0.035
Vorhandelsmarkt:
.80
0.0245
+3.16%
Schlusskurs vom Vortag:
$0.7405
Offen:
$0.77
24-Stunden-Volumen:
117.38K
Relative Volume:
0.28
Marktkapitalisierung:
$15.25M
Einnahmen:
$1.16M
Nettoeinkommen (Verlust:
$-12.02M
KGV:
-0.747
EPS:
-1.0381
Netto-Cashflow:
$-10.16M
1W Leistung:
-1.12%
1M Leistung:
-5.51%
6M Leistung:
-44.61%
1J Leistung:
-62.72%
1-Tages-Spanne:
$0.7458
$0.7895
1-Wochen-Bereich:
$0.7117
$0.88
52-Wochen-Spanne:
$0.69
$3.78
Dare Bioscience Inc Stock (DARE) Company Profile
Firmenname
Dare Bioscience Inc
Sektor
Branche
Telefon
858-926-7655
Adresse
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
0.7755 | 15.25M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Daré Bioscience launches Flora Sync LF5 for direct revenue - scanx.trade
Warrants covering about 45% of existing shares await a vote at Daré Bioscience (NASDAQ: DARE). - Stock Titan
Dare Bioscience Inc (DARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daré Bioscience publishes phase 1 sildenafil cream study data - Investing.com
Dare Bioscience (DARE) Reports Phase 1 Trial Results for Topical Sildenafil Cream - GuruFocus
Daré Bioscience publishes phase 1 sildenafil cream study data By Investing.com - Investing.com India
Sildenafil cream showed 187-fold lower peak blood levels than an oral dose - Stock Titan
Form 8K Dare Bioscience Inc For: 11 September By Investing.com - Investing.com Australia
Dare Bioscience amends bylaws to lower quorum for shareholder meetings By Investing.com - Investing.com Australia
Daré Bioscience Updates Bylaws to Ease Shareholder Quorum - TipRanks
Dare Bioscience amends bylaws to lower quorum for shareholder meetings - Investing.com
Daré Bioscience at H.C. Wainwright conference: turning to sales By Investing.com - Investing.com Canada
Daré Bioscience at H.C. Wainwright conference: turning to sales - Investing.com
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand - The Manila Times
Daré Bioscience Presentation for H.C. Wainwright 28th - GlobeNewswire
Daré Bioscience Updates Investors with New Presentation - TipRanks
DARE|Dare Bioscience Inc|Price:0.713|Chg%:-0.008 - TradingKey
Dare Bioscience (NASDAQ: DARE) Eyes Up to $12.4M from Warrants to Boost 503B and Consumer Health Initiatives - kalkinemedia.com
Dare Bioscience, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Dare Bioscience Inc (DARE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Dare Bioscience Inc (DARE) Key Financial Ratios – Valuation, Profitability & More - Value Research
Dare Bioscience (DARE) Secures $908K NIH Grant Amidst Challengin - GuruFocus
Daré Bioscience receives $908,000 NIH award for preterm birth program - Investing.com India
Daré Bioscience receives $908,000 NIH award for preterm birth program By Investing.com - Investing.com Nigeria
Daré Bioscience Announces New NIH Funding Award for - GlobeNewswire
Lind Global’s capped stake in Dare Bioscience (NASDAQ: DARE) tops key ownership threshold - Stock Titan
Dare Bioscience Inc (DARE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series - Barchart.com
IPO Databook: Daré Bioscience (DARE US)Aug 2026 - Smartkarma
Daré Bioscience publishes sildenafil cream study results - Investing.com
Daré Bioscience publishes sildenafil cream study results By Investing.com - Investing.com India
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in MenopauseThe Journal of The Menopause Society - Barchart.com
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment - Yahoo Finance
L1 Capital caps Dare Bioscience (DARE) stake at 9.99% - Stock Titan
Drugmakers still struggling to keep up with spiking estrogen patch demand - AOL.com
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - AOL.com
Dare Bioscience (NASDAQ: DARE) sets up $12.4M in potential warrant cash - Stock Titan
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - sahmcapital.com
Forbes puts a women's health biotech CEO on its 2026 innovation list - Stock Titan
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: C - GuruFocus
Dare Bioscience Prices $6.0 Million Registered Direct Offering - Minichart
Form 8K Dare Bioscience Inc For: 17 August By Investing.com - Investing.com Nigeria
Daré Bioscience Raises ~$6 Million in Equity Offering at $1.37 With Attached Warrants - TradingView
H.C. Wainwright reiterates Dare Bioscience stock rating at buy By Investing.com - Investing.com Canada
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ... - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Q2 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Finanzdaten der Dare Bioscience Inc-Aktie (DARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):